[go: up one dir, main page]

CO2020000231A2 - Composiciones inmunogénicas que comprenden cea muc1 y tert - Google Patents

Composiciones inmunogénicas que comprenden cea muc1 y tert

Info

Publication number
CO2020000231A2
CO2020000231A2 CONC2020/0000231A CO2020000231A CO2020000231A2 CO 2020000231 A2 CO2020000231 A2 CO 2020000231A2 CO 2020000231 A CO2020000231 A CO 2020000231A CO 2020000231 A2 CO2020000231 A2 CO 2020000231A2
Authority
CO
Colombia
Prior art keywords
immunogenic
polypeptide
cea
tert
muc1
Prior art date
Application number
CONC2020/0000231A
Other languages
English (en)
Inventor
Helen Kim Cho
Joseph John Binder
Paul Jason Cockle
Derek John Falconer
Siradanahalli Guru
Marianne Marcela Andrea Martinic
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CO2020000231A2 publication Critical patent/CO2020000231A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La presente descripción proporciona: (a) polipéptidos de CEA inmunogénicos aislados; (b) moléculas de ácidos nucleicos aisladas que codifican (i) un polipéptido de CEA inmunogénico, (ii) un polipéptido de CEA inmunogénico y un polipéptido de MUC1 inmunogénico, (iii) un polipéptido de CEA inmunogénico y un polipéptido de TERT inmunogénico o (iv) un polipéptido de CEA inmunogénico, un polipéptido de MUC1 inmunogénico y un polipéptido de TERT inmunogénico; (c) composiciones que comprenden una molécula de ácidos nucleicos aislada; y (d) métodos relacionados con usos de los polipéptidos de CEA inmunogénicos, moléculas de ácidos nucleicos y composiciones.
CONC2020/0000231A 2017-07-11 2020-01-10 Composiciones inmunogénicas que comprenden cea muc1 y tert CO2020000231A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762531227P 2017-07-11 2017-07-11
US201862682044P 2018-06-07 2018-06-07
PCT/IB2018/054926 WO2019012371A1 (en) 2017-07-11 2018-07-03 IMMUNOGENIC COMPOSITIONS COMPRISING CEA MUC1 AND TERT

Publications (1)

Publication Number Publication Date
CO2020000231A2 true CO2020000231A2 (es) 2020-01-17

Family

ID=63720720

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0000231A CO2020000231A2 (es) 2017-07-11 2020-01-10 Composiciones inmunogénicas que comprenden cea muc1 y tert

Country Status (16)

Country Link
US (1) US20190016775A1 (es)
EP (1) EP3651792A1 (es)
JP (2) JP7028953B2 (es)
KR (1) KR20200027551A (es)
CN (1) CN111065408A (es)
AU (1) AU2018300295A1 (es)
BR (1) BR112020000413A2 (es)
CA (1) CA3069363A1 (es)
CO (1) CO2020000231A2 (es)
IL (1) IL271917A (es)
PE (1) PE20200613A1 (es)
PH (1) PH12020500087A1 (es)
RU (1) RU2020100072A (es)
SG (1) SG11202000197PA (es)
TW (1) TW201920674A (es)
WO (1) WO2019012371A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102020201219A1 (de) 2020-01-31 2021-08-05 United Initiators Gmbh Transport- und Lagerbehälter für Peroxide
CN112552380B (zh) * 2020-12-10 2021-12-24 武汉博沃生物科技有限公司 一种SARS-CoV-2病毒的免疫原及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5288641A (en) 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
CA1341423C (en) 1984-10-31 2003-03-04 Paul A. Luciw Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
US5591624A (en) 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
US5716826A (en) 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5817491A (en) 1990-09-21 1998-10-06 The Regents Of The University Of California VSV G pseusdotyped retroviral vectors
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US6962790B1 (en) 1998-09-23 2005-11-08 University Of Massachusetts Medical Center Predictive assay for immune response
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
ATE354655T1 (de) 1999-08-24 2007-03-15 Medarex Inc Humane antikörper gegen ctla-4 und deren verwendungen
TWI228718B (en) 2001-11-05 2005-03-01 Tdk Corp Manufacturing method and device of mold plate for information medium
DE10162480A1 (de) * 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
WO2005071093A2 (en) 2004-01-23 2005-08-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Chimpanzee adenovirus vaccine carriers
ES2376010T3 (es) * 2006-10-12 2012-03-08 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.R.L. Prote�?na de fusión de transcriptasa inversa de la telomerasa, nucleótidos que la codifican y usos de la misma.
SI2315756T1 (sl) 2008-07-08 2014-12-31 Incyte Corporation Experimental Station 1,2,5-oksadiazoli kot inhibitorji indolamin 2,3-dioksigenaze
EP2391638B1 (en) 2009-02-02 2018-06-27 GlaxoSmithKline Biologicals SA Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
US9128725B2 (en) 2012-05-04 2015-09-08 Apple Inc. Load-store dependency predictor content management
HUE033369T2 (en) * 2012-11-20 2017-11-28 Sanofi Sa Anti-CEACAM5 antibodies and their applications
JP2014161283A (ja) * 2013-02-26 2014-09-08 Shizuoka Prefecture Ｃｅａｃａｍ５遺伝子のスプライシングバリアント
MX369154B (es) * 2013-08-21 2019-10-30 Curevac Ag Composición y vacuna para tratar cáncer de pulmón.
CA2928542A1 (en) 2013-10-28 2015-05-07 Piramal Enterprises Limited Herbal composition, process for its preparation and use thereof
KR102006527B1 (ko) 2013-11-01 2019-08-02 화이자 인코포레이티드 전립선-연관 항원의 발현을 위한 벡터
EP3148531A1 (en) 2014-05-15 2017-04-05 iTeos Therapeutics Pyrrolidine-2,5-dione derivatives, pharmaceutical compositions and methods for use as ido1 inhibitors
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
US11352642B2 (en) * 2015-01-09 2022-06-07 Etubics Corporation Methods and compositions for combination immunotherapy

Also Published As

Publication number Publication date
JP2020526202A (ja) 2020-08-31
JP2022031653A (ja) 2022-02-22
SG11202000197PA (en) 2020-02-27
JP7028953B2 (ja) 2022-03-02
WO2019012371A1 (en) 2019-01-17
IL271917A (en) 2020-02-27
BR112020000413A2 (pt) 2020-07-21
KR20200027551A (ko) 2020-03-12
RU2020100072A3 (es) 2021-08-11
PE20200613A1 (es) 2020-03-11
PH12020500087A1 (en) 2020-09-14
US20190016775A1 (en) 2019-01-17
CN111065408A (zh) 2020-04-24
TW201920674A (zh) 2019-06-01
AU2018300295A1 (en) 2020-01-23
EP3651792A1 (en) 2020-05-20
CA3069363A1 (en) 2019-01-17
RU2020100072A (ru) 2021-08-11

Similar Documents

Publication Publication Date Title
CY1123932T1 (el) Δομες πολυειδικου αντισωματος
PE20142406A1 (es) Antigenos asociados a prostata y regimenes de inmunoterapia basados en vacuna
EP3950941A3 (en) Dnase polypeptide variants
CY1124806T1 (el) Αντισωματα enanti-cd40 και χρησεις αυτων
SA518400424B1 (ar) جزيئات الجسم المضاد لعلاج السرطان
CO2019000395A2 (es) Genes de mini–distrofina optimizados y casetes de expresión y su uso
BR112019000195A2 (pt) composições e métodos relacionados a sistemas celulares terapêuticos que expressam rna exógeno
BR112018011073A2 (pt) anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes e métodos de utilização
BR112018070934A2 (pt) proteínas imunomoduladoras variantes ligantes de icos e usos das mesmas
CO2018009120A2 (es) Genes del factor viii optimizados
CL2017002820A1 (es) Variantes de alfa-amilasa y polinucleótidos que codifican las mismas
ECSP19011185A (es) Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a CD3 y CD123
BR112018074463A2 (pt) anticorpos anti-tim-3 e métodos de uso dos mesmos.
BR112018072946A2 (pt) proteínas de fusão a gdf15 e usos das mesmas
BR112017014031A2 (pt) n-oligossacaril-transferase recombinante, mutante de n-oligossacaril-transferase recombinante, ácido nucleico, célula hospedeira, e, método para produção de um bioconjugado.
EP3741848A3 (en) Protease variants and polynucleotides encoding same
MX2021010668A (es) Proteinas de fusion de citoquinas.
MX2016015235A (es) Nuevos polipeptidos de union especifica y usos de los mismos.
BR112017023692A2 (pt) moléculas imunoterapêuticas glican-dependentes
EP3964575A3 (en) Alpha-amylase variants and polynucleotides encoding same
AR102950A1 (es) Variantes de lipasa y polinucleótidos que las codifican
CO2018007442A2 (es) Vacunas contra el cáncer
CL2018000164A1 (es) Vector recombinante del virus orf.
BR112016025898A2 (pt) ?drimenol sintases e método para produzir drimenol?
UY36617A (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer